BPC-157 Pipeline, FDA Status, and What Comes Next

What BPC-157 actually is

BPC-157 is a synthetic peptide of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice [1]. It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1]. FDA noted websites selling BPC-157, alone or blended with TB-500, as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use' [1].

Where BPC-157 stands with FDA right now

Three separate statuses get mixed together, so keep them apart.

Approval: none. BPC-157 is not an FDA-approved drug, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

Compounding list: not on it. FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, places BPC-157 in none of its three categories, so the Category 1 policy, which is the group FDA says it generally will not act against compounders for if conditions are met, does not cover it [7].

Significant-safety-risk table: no longer there. BPC-157 sat in Category 2 from September 2023 until April 22, 2026, when it moved to a 'nominated but withdrawn' table after the groups that nominated it withdrew their nominations [4][8]. Removal was not a finding of safety. FDA's stated concerns stay on the page: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient, and FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' and 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [4].

One backdrop applies to any compounded version: compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [9].

What happened at the July 2026 advisory committee

FDA's Pharmacy Compounding Advisory Committee met on July 23, 2026 to discuss BPC-157 free base and BPC-157 acetate for the use FDA evaluated, ulcerative colitis [2]. FDA's own reviewers had proposed that BPC-157 not be added to the pharmacy bulks list, citing poor chemical characterization, little information on safety and immunogenicity, insufficient evidence that it works for ulcerative colitis, and several already-approved drugs for that condition [1]. The committee voted in favor of adding it anyway; news reports give the vote as 8 to 6 with 1 abstention [2].

That vote is advice. BPC-157 is not on the list, and adding it requires formal rulemaking: a proposed rule, a public comment period, and a final rule [2][8].

The HHS draft policy, and what it does not do

On October 28, 2026 HHS filed notice of a draft enforcement-discretion policy covering six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [3][8]. Federal Register publication was scheduled for October 30, 2026, with public comments open for two weeks after publication [3][8]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3][8].

The conditions written for BPC-157 are specific [8]:

• BPC-157 acetate only
• subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous are not listed
• a single active ingredient
• bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard
• a label reading 'This is a compounded drug product. Not for resale.'
• a patient-specific prescription
• serious adverse events and quality problems reported to FDA MedWatch
• only an FDA 510(k)-cleared syringe as a co-packaged device
• for oral forms, documentation of adequate bioavailability

The draft policy is not an approval and does not put BPC-157 on any list. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue appears [3][8]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, the larger registered compounders; BPC-157 is also absent from FDA's list for outsourcing facilities, updated March 21, 2025 [3][8][10].

What comes next in the pipeline

The compounding track. FDA would publish a proposed rule adding BPC-157 to the bulks list, take comments, then finalize. Until a final rule exists, BPC-157 stays off the list, whatever the advisory committee said [2][8].

The drug-development track. Any effort to seek FDA approval would need to address substantial gaps in the evidence about BPC-157's effectiveness and safety in people [1][5]. FDA identified only a handful of small human studies, among them a 17-patient retrospective chart review of knee injections, a single-arm pilot in 12 women with interstitial cystitis and a 2-person intravenous pilot, as well as meeting abstracts [1][11][12][13]. FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1]. A 2026 systematic review searching to June 1, 2026 found only 3 studies covering 30 patients in orthopaedic and regenerative use, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [5].

The ulcerative colitis trial FDA evaluated exists only as a meeting abstract (Gastroenterology 2005): 53 people with mild to moderate disease randomized to an 80 mg BPC-157 enema or placebo daily for 2 weeks, reported as well tolerated with no difference in adverse events versus placebo. FDA said the abstract has too little detail to judge effectiveness, and no full paper exists [1].

Doses reported in the few human studies

FDA found no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

What has been given in the few human reports: rectal enemas up to 2 mg/kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice for knee pain; 10 mg injected around the bladder wall once for interstitial cystitis; and 10 mg then 20 mg intravenously on two days in 2 healthy adults [1]. None of these is a recommended dose, and there is no approved dose for an unapproved product [1].

What a developer would still have to answer

Mechanism. FDA said BPC-157's molecular targets have not been identified, its mechanisms 'remain poorly understood', and dose-response relationships for the reported protective effects were not established. The reported effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [1].

Safety in humans. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. Its adverse-event database search through December 4, 2025 turned up 3 reports, all involving injectable product: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit, with no other detail; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused these [1]. In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information [1].

Animal signals. In 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels. Longer studies and cancer-risk studies were not available [1].

Does the regulatory news change the sports ban?

No. WADA's Prohibited List names BPC-157 in S0 (non-approved substances), which covers substances with no current approval by any governmental regulatory health authority for human therapeutic use; it is prohibited at all times, in and out of competition, and the 2026 List has been in force since January 1, 2026 [6]. BPC-157 was first named as an example under S0 in the 2022 List and stays named in the 2027 List, approved September 10, 2026 and in force January 1, 2027 [15][16]. The advisory vote and the HHS draft policy are not approvals [2][3].